7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule

Post-Transplant Re-Vaccination, Infection Prevention & Survivorship Care Plans

Quick Clinical Summary: HCT can erase or weaken prior vaccine protection, so recipients are generally revaccinated with a primary-series approach. Timing is vaccine- and patient-specific: pneumococcal vaccination commonly begins 3–6 months after HCT, other inactivated vaccines follow the current transplant schedule, and live vaccines are considered no earlier than 24 months only when the patient is immunocompetent, has no active GVHD, and is off immunosuppression. A survivorship plan records doses, deferrals, immune therapy/IVIG context, responsibilities, and follow-up.

1. Post-Transplant Immune Reconstitution & Rationale for Re-Vaccination

Following conditioning and stem cell infusion, the recipient's immune system undergoes a protracted, recapitulated ontogeny:

IMMUNE RECOVERY AFTER HCT

Early: innate-cell recovery and profound infection risk
  -> Next: variable NK/T-cell recovery, still influenced by conditioning, GVHD and therapy
      -> Later: B-cell, antibody and naive-T-cell recovery may remain incomplete for months to years
          -> Vaccination decisions use vaccine-specific timing plus the patient's current immune state

Why Pre-Transplant Immunity Is Lost

• Humoral Ablation: Conditioning chemotherapy and irradiation destroy host plasma cell niches in bone marrow and spleen.
• Donor Titer Decay: While donor memory B cells are transferred in allogeneic grafts, they fail to maintain protective antibody titers beyond 6 to 12 months without scheduled antigen re-exposure.
• Thymic Delay: Regeneration of naive CD4+ helper T cells (CD4+CD45RA+) via the thymus is exceedingly slow, especially in adults or patients who suffered GVHD-mediated thymic epithelial damage. Without CD4+ help, B cells cannot undergo effective class-switching or long-lived memory generation without booster vaccinations.

2. Inactivated Re-Vaccination Schedule

Inactivated, recombinant, toxoid, and subunit vaccines cannot replicate. Start dates vary by vaccine, transplant type, outbreak/season, GVHD and immunosuppression, and expected response. The example below highlights the current CDC pneumococcal sequence; the transplant team should issue a patient-specific schedule rather than treating every row as one universal month:

Current pneumococcal sequence example

• Begin PCV20 about 3–6 months after HCT when clinically appropriate.
• Give three PCV20 doses at least 4 weeks apart.
• Give a fourth PCV20 dose at least 6 months after dose 3 or at least 12 months after HCT, whichever is later.
• If another pneumococcal product is used, follow the current CDC alternative schedule.

3. Executing the Schedule at the Bedside

A vaccine schedule fails in practice for administrative reasons far more often than clinical ones, and most of those failures are preventable at the point of administration.

Verify eligibility at each dose, not once at the start. Immunosuppression, GVHD activity, recent antibody products, and B-cell-depleting therapy all change between visits. A patient cleared for a series in month six may be back on systemic therapy by month nine, so confirm current status against the plan before each administration rather than assuming the series carries forward.

Manage the injection in a thrombocytopenic patient. Intramuscular administration is generally acceptable at platelet counts the program considers safe, using the smallest appropriate needle gauge, avoiding aspiration, and applying firm pressure without rubbing for at least two minutes afterward. When counts are very low, coordinate the timing with the count trend or with a planned transfusion rather than deferring the vaccine indefinitely, and document the site so a subsequent hematoma can be attributed.

Document what a future clinician will need. Record product, manufacturer, lot number, expiration, dose, route, site, and date, plus the immunosuppression status at administration. A dose given during active immunosuppression may need to be repeated, and that judgment is impossible without the context.

Close the loop on serology where it is indicated. Some vaccines, notably hepatitis B, may be followed by post-series serologic testing with revaccination when the response is inadequate. Order sets do not always include it, and the result frequently arrives after the patient has transitioned to community care, so name the responsible clinician in the survivorship plan.

Reconcile against the immunization registry. Doses given at pharmacies, in the community, or during travel do not automatically appear in the transplant record. Check the registry at milestone visits and reconcile discrepancies rather than assuming the chart is complete.